Introduction {#Sec1}
============

The time course of synaptic currents is one of the main factors determining how a single neuron integrates information coming from different inputs. The duration of postsynaptic currents can vary over two orders of magnitude depending on the kinetics of the postsynaptic receptors being activated. For example, excitatory glutamatergic currents decay with time constants (*τ*~decay~) as short as 2 ms when mediated by AMPA receptors alone (AMPARs), while the recruitment of NMDA receptors (NMDARs) prolongs the decay up to hundreds of milliseconds. Similarly, glycine-receptor-mediated inhibitory currents are fast (*τ*~decay~ ∼ 3 ms) while GABA~A~ receptor (GABA~A~R) mediated events are approximately three to four times slower. Since these receptors operate in conditions of non-equilibrium, small variations in the neurotransmitter profile can alter considerably the time course of synaptic currents. It is normally thought that, following release, neurotransmitters in the cleft reach a peak concentration that is in the millimolar range, and decays rapidly (*τ*~decay~ = 0.1--1 ms), due to diffusion, re-uptake, binding to receptors/transporters, or enzymatic breakdown. However, at some synapses in the central nervous system, receptors are exposed to small and prolonged neurotransmitter transients \[[@CR1]--[@CR4]\]. This longer concentration profile gives rise to synaptic currents that decay slowly (depending on the kinetic properties of the receptors) and leads to an extended period of synaptic excitation or inhibition. Therefore, determining the concentration profile of neurotransmitters released during synaptic events is essential for understanding the effects of individual synaptic inputs onto their corresponding postsynaptic targets. The major difficulties to address this issue experimentally are posed by the inaccessibility of narrow synaptic clefts, uncertainties in the ultrastructure, and physical constraints to neurotransmitter diffusion within and outside the cleft, and by the fact that synapses vary widely in shape, size, density of neurotransmitter receptors, and quantal properties of neurotransmitter release \[[@CR5]--[@CR10]\]. As a consequence, estimates of the neurotransmitter time course can only be rough approximations, often representing average estimates obtained through indirect approaches, primarily pharmacological, which can only partially characterize a few aspects of this phenomenon.

Here, we discuss the various features of synaptic release that can lead to different neurotransmitter concentration profiles in the cleft. We describe the pitfalls and advantages of the experimental approaches used so far, and briefly overview some of the emerging imaging approaches that could refine current estimates of the neurotransmitter lifetime once liberated in the synaptic cleft.

Quantal Size and Multivesicular Release {#Sec2}
=======================================

At first sight, an estimate of the neurotransmitter concentration profile in the synaptic cleft could be easily obtained if one knew how many neurotransmitter molecules are stored in each synaptic vesicle, how many vesicles fuse with the presynaptic terminal in response to an action potential, and how much of the vesicle content is released in the synaptic cleft with every partial or full fusion event. In practice, getting detailed information about each one of these steps has proven to be a challenging task.

The first attempt to measure how much neurotransmitter is released at the neuromuscular junction was probably done by Acheson \[[@CR11]\], who suggested that 10^−15^ mmoles acetylcholine (ACh) is released per presynaptic nerve stimulation. This value was inferred from titration experiments through exogenous ACh applications which, however, reproduced only roughly the time course of miniature end-plate potentials (mEPPs). Iontophoresis approaches proposed a tenfold increase in the above value (10^−14^ mmoles \[[@CR12]\]), but still suffered from profound underestimates of ACh dilution from the iontophoresis pipette to the end-plate and presumably from overestimates of the end-plate area where the ACh receptors (AChRs) are distributed (the fraction of the total iontophoretic current passed by ACh was also an approximation \[[@CR13]\]). The major breakthroughs came from two studies that provided information on: (1) the postsynaptic area activated by a quantum of neurotransmitter (\<2 μm^2^ \[[@CR14]\]); (2) the number of ACh molecules released by each quantum \[[@CR13]\]. It is worth noting that for the experiments described by \[[@CR13]\], the snake end-plate preparation was placed in an oil--water interface, which therefore minimized the dilution artifacts mentioned previously. The authors performed two consecutive titrations to calculate the charge that had to be applied to the iontophoresis pipette to reproduce a mEPP reasonably accurately, and the number of ACh molecules released from the iontophoresis pipette per unit of charge. The final approximation of \<10^4^ ACh molecules/vesicle suggested that in a postsynaptic area of 1 μm^2^, with a 50-nm-wide synaptic cleft, the peak ACh concentration is \~0.3 mM, and in a 50-nm-wide synaptic vesicle the ACh concentration is \~260 mM \[[@CR13]\]. There is rough agreement between these estimates and the more detailed ones obtained later on at the frog and mouse neuromuscular junctions (peak neurotransmitter concentration in the cleft \~1 mM, but see Fig. [2](#Fig2){ref-type="fig"} in \[[@CR15]\] for an evaluation of how the ACh concentration changes as it spreads over the postjunctional area). Therefore, to this day, the hypothesis that synaptically released ACh reaches millimolar concentrations at the neuromuscular junction remains the most widely accepted.

The use of carbon-fiber microelectrodes and amperometry has been instrumental to obtaining analogous estimates from cells that release electro-oxidizable molecules such as catecholamines and indoleamines. Although the technique was initially developed to detect neurotransmitter release from chromaffin cells \[[@CR16]\], it has also been used on central neurons \[[@CR17]\]. Briefly, electro-active neurotransmitters are oxidized by the carbon-fiber, and the reaction causes a positive deflection in the current measurement obtained through the microelectrode. A read-out of the vesicular neurotransmitter concentration is readily obtained by converting the charge transfer during the positive deflection into number of moles by using Faraday's constant. Accordingly, $$\documentclass[12pt]{minimal}
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\begin{document}$$ N = \frac{Q}{{n \cdot F}} $$\end{document}$$where *N* = number of moles of neurotransmitter, *Q* = charge transfer per positive deflection (C), *n* = number of electrons involved in the reaction, *F* = Faraday constant. It was estimated that the vesicular concentration of catecholamine in chromaffin cells is 190--300 mM \[[@CR16]\] and that of dopamine in midbrain neurons is \~300 mM \[[@CR17]\].

Amperometric measures offer excellent time resolution, but because neurotransmitters are degraded as they react with the carbon-fiber, estimates of the time course of release can potentially be slightly inaccurate (i.e., the neurotransmitter concentration decreases as it reacts with the carbon-fiber). The major limitations of this technique, however, are posed by the facts that carbon-fibers (which have a diameter of a few micrometers) cannot access the synaptic cleft (which has a width of tens of nanometers), and are not suited for neurotransmitter concentration measurements at synapses that do not release non electro-oxidizable molecules.

At central synapses, direct measures of the vesicular concentration of glutamate (as well as GABA, glycine, and other neurotransmitters) have not been obtained. However, numerous biochemical studies have been crucial to provide some sort of ballpark figure. For example, immunoisolation of synaptic vesicles with antibodies against synaptophysin has shown that, under experimental conditions that enable the maintenance of an energy gradient across the vesicular membrane, glutamate is ten times more concentrated in synaptic vesicles that in the cytoplasm \[[@CR18]\]. Given that (1) there is \~0.8 μmol glutamate/mg synaptophysin, (2) synaptophysin represents \~7% of total vesicle proteins, (3) the volume of synaptic vesicles is assumed to be \~1 μl/mg total protein, it was suggested that the glutamate concentration in synaptic vesicles is \~60 mM, and certainly \<150 mM, a value imposed by the Donnan law \[[@CR18]\]. These estimates are in rough agreement with those obtained from synaptic vesicles isolated with other purification protocols, yielding values of 70--210 mM \[[@CR19]\].

It is worth noting, however, that all these quantifications have been obtained through a series of conversions that at some point require knowledge of the inner volume of synaptic vesicles. This information has been traditionally obtained through electron microscopy studies, but the size of synaptic vesicles can be altered by the chemical fixation steps required for tissue preparation (see \[[@CR20]\] for one of the most detailed analyses of synaptic vesicle structure). Since the synaptic vesicle volume scales with the third power of its radius, small errors in length can lead to much bigger errors in volumes. Therefore, it is still unclear whether the synaptic vesicle volume varies significantly across the entire population of synaptic vesicles in presynaptic terminals \[[@CR20], [@CR21]\] or not \[[@CR22]\]. There is also some debate on whether the neurotransmitter concentration varies across synaptic vesicles of different size \[[@CR23], [@CR24]\], or with different copies of vesicular neurotransmitter transporters \[[@CR25]\]. Since the final neurotransmitter concentration in the cleft depends on the total number of neurotransmitter molecules released, vesicles with similar neurotransmitter concentration but different volume can still lead to different neurotransmitter concentration profiles in the cleft.

Do synapses always release one vesicle or are they also capable of releasing more than one? Despite the fact that multiple vesicles are docked at most presynaptic terminals, the number of active synaptic connections among neurons generally exceeds the total number of quanta released during synaptic stimulations \[[@CR26], [@CR27]\]. This combined anatomical and electrophysiological evidence has led to the hypothesis that, at various peripheral and central synapses, not more than one vesicle of neurotransmitter is released from a given active zone (univesicular release hypothesis) \[[@CR28], [@CR29]\]. If the hypothesis holds for those single-site connections where quantal events can be clearly resolved (i.e., when miniature events are much bigger than the baseline noise of the recordings, and are not distorted by the cable properties of neuronal dendrites \[[@CR30]\]), it does not necessarily imply a unique mode of release in time and across the different synaptic contacts that a neuron forms \[[@CR31]\].

In the last decade, numerous studies have proposed that multiple release events can also occur (multivesicular release hypothesis) \[[@CR30], [@CR32]--[@CR41]\]. One line of evidence in support of multivesicular release is the occurrence of miniature currents that arise in brief succession, do not summate linearly, and are not independent on one other \[[@CR30]\]. A more indirect approach relies on the measure of the amplitude of evoked EPSCs when varying release probability (*P*~R~) in the presence of low-affinity competitive antagonists \[[@CR32], [@CR34], [@CR40]\] (described in a following section of this review). Such antagonists are less efficient in blocking the response when the receptors are exposed to higher concentrations of neurotransmitter. Consequently, if increasing *P*~R~ increases the amount of neurotransmitter released from individual synapses (as suggested by the multivesicular release hypothesis), it also leads to reduced sensitivity of postsynaptic currents to low-affinity antagonists. Conversely, if increasing *P*~R~ only increases the number of active synapses, but each synapse still releases one quantum, no change in the effect of low-affinity antagonists on postsynaptic currents is expected \[[@CR32], [@CR34], [@CR40]\]. Multivesicular release can result in a prolonged exposure time of postsynaptic receptors to the agonist if the neurotransmitter vesicles are not released simultaneously, thereby leading to postsynaptic currents that decay more slowly. This, however, is a rather unspecific effect, that can arise for other reasons than multivesicular release. For example, it can occur when varying the mode of vesicle fusion \[[@CR42]\] or the extent of neurotransmitter spillover among neighboring synapses \[[@CR43]\]. A clear distinction between these scenarios is difficult to establish and it is probably for this reason that it remains arduous to unequivocally prove the occurrence of multivesicular release at certain synapses.

The extent to which the neurotransmitter concentration profile in the cleft is altered by multivesicular release also depends on the temporal characteristics of each synaptic vesicle fusion, and on the number of neurotransmitter molecules released during successive fusion events. For example, if only a few neurotransmitter molecules were released in the cleft during the second fusion, the profile of the neurotransmitter transient would be only marginally different from that observed when univesicular release takes place.

From a functional standpoint, having the ability to release more than one synaptic vesicle endows synapses with the ability to expand their dynamic range of outputs in response to synaptic stimulations and presumably to enhance the reliability with which information is conveyed from one neuron to the other. This simple scenario, however, may be complicated by the fact that the magnitude of the postsynaptic response and the pattern of activity of the postsynaptic neuron can be shaped by non-linear interactions between neurotransmitter receptors and voltage-gated conductances \[[@CR41]\].

Partial Versus Full Fusion Events {#Sec3}
=================================

Ca^2+^ entry in the presynaptic terminal triggers a complex cascade of events that ultimately results in fusion of neurotransmitter vesicles with the presynaptic membrane. Whether this process involves complete or transient fusion between vesicles and synaptic terminals remains a hotly debated issue that began with the ultrastructural detection of omega-shaped profiles at the active zone of the neuromuscular junction after prolonged electrical stimulation \[[@CR44], [@CR45]\]. Because electron microscopy only provides a snapshot of an ongoing process, however, it remained unclear whether these structures represented a vesicle in the process of releasing its content \[[@CR45]\] or one that was being immediately retrieved \[[@CR44]\]. Since these initial observations a number of functional approaches ranging from amperometry \[[@CR46]\] to capacitance measurements \[[@CR47]\] and imaging of fluorescent styryl dyes and pH sensors \[[@CR48], [@CR49]\] have confirmed the occurrence of transient fusion although, to date, it remains unclear whether this represents a typical or rare mode of neurotransmitter release.

At some synapses, the net prevalence of partial/full fusion events can be tested by performing capacitance measurements from the presynaptic terminal \[[@CR47]\]. Since membrane capacitance is linearly proportional to cell surface, it increases any time a vesicle fuses with the presynaptic membrane. Accordingly, step-like increases and decreases in cell capacitance have been observed in chromaffin cells and neurons \[[@CR47], [@CR50], [@CR51]\]. These are attributed to vesicle fusion and retrieval events, respectively, because (1) the amplitude distribution of capacitance steps matches that of synaptic vesicle surface area obtained through morphological studies \[[@CR51], [@CR52]\]; (2) the time course of fluorescence loss from dye-loaded synaptic vesicles matches that of cell capacitance increase \[[@CR52]\]; (3) the frequency of the up-steps, like that of release events, depends on the external \[Ca^2+^\] and drops in the presence of the protease trypsin \[[@CR47]\]; (4) up-steps can only be recorded from the side of presynaptic terminals that faces the postsynaptic cell \[[@CR47]\].

The capacitance measurements are generally performed by coupling a phase lock-in amplifier with a voltage-clamp amplifier. The cell (or the patch, if the recordings are in cell-attached configuration) is voltage-clamped and forced to undergo sinusoidal voltage membrane oscillations. The lock-in amplifier decomposes the real (Re) and imaginary components (Im) of the admittance, which are in-phase and 90°-out-of-phase with the membrane voltage, respectively. Changes in Re reflect conductance changes, whereas changes in Im reflect changes in capacitance. Therefore, one can also obtain information on the fusion pore conductance (*G*~P~) by applying the equation: $$\documentclass[12pt]{minimal}
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\begin{document}$$ {D_{\text{P}}} = \sqrt {\frac{{4{G_{\text{P}}}\rho \lambda }}{\pi }} $$\end{document}$$(*ρ* = saline resistivity (100 Ω cm), *λ* = pore length (generally set at 15 nm, the length of a gap junction hemichannel)) \[[@CR53]\]. The time constant of neurotransmitter discharge can be described as: $$\documentclass[12pt]{minimal}
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\begin{document}$$ \tau = \frac{{\pi d_{\text{V}}^3}}{{6\rho {D^*}{G_{\text{P}}}}} $$\end{document}$$(*d*~V~ = vesicle diameter, *D*\* = apparent neurotransmitter diffusion constant).

At the calyx of Held, 97% of the events detected with capacitance measurements have *G*~P~ \> 288 pS and *D*~P~ \> 2.3 nm, and are interpreted as full fusion events because they can lead to complete neurotransmitter release from synaptic vesicles in *τ* \< 0.54 ms. If this were true, miniature excitatory postsynaptic currents (mEPSCs) would be predicted to rise with 10--90% rise time = 0.15--0.36 ms, a range that closely matches the one observed experimentally for most mEPSCs (0.21--0.27 ms) \[[@CR47]\]. For the remaining 3% of the events *G*~P~ = 66 pS, leading to *D*~P~ = 1.1 nm and *τ* = 2.3 ms \[[@CR47]\]. In this case, the probability of releasing completely the synaptic vesicle content in the extracellular space (ECS) depends on how long the fusion pore remains open. This parameter varies across a relatively broad range (10 ms--1 s), so that the rare occurrence of non-quantal events cannot be completely ruled out.

At hippocampal synapses, partial fusion (although not necessarily partial neurotransmitter discharge) initially emerged as the predominant mode of neurotransmitter release \[[@CR54], [@CR55]\]. This feature has been proposed to speed the recycling time of synaptic vesicles substantially, to 1--2 s \[[@CR54]\] (cf. 15--20 s for clathrin-mediated endocytotic pathways \[[@CR56], [@CR57]\]), and therefore enable reliable synaptic transmission during high-frequency stimulation. Such a fast recycling time would be primarily limited by the time of vesicular reacidification via the H^+^-pump and of neurotransmitter refilling through vesicular transporters. It should be noted, however, that this net prevalence of partial fusion events is not unanimously observed \[[@CR57], [@CR58]\] and may be biased by some methodological and analytical caveats \[[@CR57]\]. For example: (1) lack of complete FM1-43 loss from synaptic vesicles may reflect dye partitioning in membranes neighboring the site of neurotransmitter release, rather than the occurrence of partial fusion events; (2) the fast decline in the fluorescence of the pH-sensitive GFP synaptopHluorin after exocytosis may be due to diffusion of the indicator away from the release site rather than to rapid endocytosis, and can be accounted for by enlarging the region of interest used for quantifying fluorescent signals \[[@CR57]\]. The incidence of partial fusion events may vary across synapses with different release probabilities or experiencing different levels of synaptic stimulation \[[@CR49]\], and possibly changes during development \[[@CR59]\], but additional work will help to test these hypotheses in further detail \[[@CR57]\].

One intriguing approach that has been recently used to measure the likelihood of partial/full fusion events involves the use of quantum dots as reporters of different vesicular pH and fusion modes \[[@CR49], [@CR60]\]. Quantum dots with a hydrodynamic diameter of \~15 nm (matching the intravesicular diameter) have a peak emission at 605 nm, with an intensity that apparently increases with pH \[[@CR49]\]. The acidic pH of synaptic vesicles (5.5) rises to extracellular values (7.4) upon opening of the fusion pore. The consequent increase in the fluorescence signal from the quantum dots is recovered if the fusion pore closes back (partial fusion), but is followed by an irreversible loss of fluorescence if the quantum dot is released into the extracellular environment (full fusion) \[[@CR49]\]. This approach suggests that partial fusion is limited to \~20% of all fusion events, and involves primarily synaptic vesicles with relatively high intrinsic release probability (readily releasable pool \[[@CR49]\]). A prevalence of full fusion events would shift the source of variability in the peak concentration of released neurotransmitter to differences in vesicle size and vesicle filling that we mentioned in the previous chapter \[[@CR25]\].

In addition to the mode of release, the lifetime of the neurotransmitter in the ECS is also affected by a number of other factors. Once released into the synaptic cleft, the neurotransmitter is subject to three main phenomena: (1) binding to postsynaptic receptors or to degrading enzymes in the ECS; (2) diffusion and escape from the synapse; (3) binding to nearby transporter molecules. All these processes act in a concerted, but not necessarily simultaneous, way to rapidly terminate the neurotransmitter actions and enable reliable high-frequency signaling among neurons. In the next sections, we analyze how each one of them contributes to shape the lifetime of neurotransmitters in the synaptic cleft.

Neurotransmitter Enzymatic Breakdown and Receptor Binding {#Sec4}
=========================================================

At the neuromuscular junction, mEPPs rise in \<1 ms and decay with a half-time of about 1--1.5 ms at room temperature. The duration and variability of mEPPs is enhanced in the presence of molecules like prostigmine or eserine, which inhibit the activity of ACh esterase, the degrading enzyme for ACh present in the ECS \[[@CR61]--[@CR63]\]. Hydrolysis of ACh is generally thought to be rapid and, based on the previous observations, to represent the major mechanism responsible for the fast time course of mEPPs at the neuromuscular junction \[[@CR62]\]. When the enzymatic breakdown of ACh is reduced, however, the decay of mEPPs (3.5--4 ms) is not entirely accounted for by free diffusion of the neurotransmitter away from the cleft (2 ms \[[@CR64]\]), estimated through a simple analytic approach initially described by \[[@CR65]\] and \[[@CR66]\]. What other mechanism could underlie this discrepancy? Although one would have been naturally inclined to dismiss the accuracy of the adopted mathematical model, Katz and Miledi \[[@CR62]\] perceptively noticed that the effects of ACh esterase inhibitors on the decay of mEPPs could be partially counteracted by curare or α-bungarotoxin, antagonists of the nicotinic AChRs mediating the mEPPs. These drugs, per se, reduced the amplitude of the mEPPs, as well as their variability and decay time. The proposed hypothesis was that ACh unbinding and rebinding to its receptors delays the neurotransmitter clearance from the synaptic cleft. If one assumes that there are more AChRs than ACh molecules released during synaptic events, and that curare unbinding from AChRs is negligible during the time course of the mEPPs, then the duration of the ACh transient becomes inversely proportional to the number and lifetime of ACh--AChRs complexes. That is to say: if *p* is the fraction of ACh molecules initially bound to AChRs, the decay of the ACh transient is 1/(1 − *p*) slower than what it would be in the case of free diffusion (*p* = 0). This delay, as well as the variability of mEPPs amplitude, is largely reduced by curare because by lowering *p* the drug brings the time course of cholinergic events close to the lifetime of single ACh--AChRs complexes.

The proposed mechanism strongly depends on the kinetic profile of the AChR-antagonist interaction and consequently may not be equally relevant for other pharmacological compounds. More importantly, it is unlikely to have a major impact when the density of postsynaptic receptors is low (like at central synapses and, possibly, at the neuromuscular junction itself). Although ACh is broken down extracellularly, apart from ATP and peptides, other transmitters are not degraded. Rather, they are subject to diffusion and reuptake, which therefore represent the main phenomena that shape the time course of synaptic events.

Diffusion and Reuptake {#Sec5}
======================

The time course of the concentration change of a solute in a solution is quantitatively described by Fick's second law of diffusion: $$\documentclass[12pt]{minimal}
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\begin{document}$$ \frac{{\partial {C_x}}}{{\partial t}} = D\frac{{{\partial^2}{C_x}}}{{\partial {X^2}}} $$\end{document}$$where *C*~*x*~ = concentration of the solute at distance *x* from a reference point, *D* = diffusion coefficient of the solute in free, aqueous solution, and *t* = time. This formalism, which describes the temporal development of a concentration profile in a homogeneous and free medium, cannot be used as it is to define the movement of neurotransmitter molecules in the brain. The brain may not necessarily behave as a homogeneous (or isotropic) medium (although this may be a more or less of a concern for different brain regions); the apparent diffusion coefficient of the neurotransmitter in the ECS (*D*\*) is generally smaller than the one measured in free solution (*D*), due to the geometrical and molecular complexity of the ECS in respect to free medium \[[@CR67]\]; part of the neurotransmitter molecules can be removed from the ECS as they are enzymatically degraded or taken up by transporters. An evaluation of the applicability of Fick's second law to the brain environment has been proposed by Nicholson and Phillips \[[@CR67]\], by approximating this structure to a porous medium with extracellular volume fraction *α* and tortuosity *λ*. The equation, which now reads: $$\documentclass[12pt]{minimal}
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\begin{document}$$ \lambda = \sqrt {{D \mathord{\left/{\vphantom {D {{D^* }}}} \right.} {{D^* }}}} $$\end{document}$). It does not change significantly with development (*λ* ∼ 1.6), but may vary across different brain regions and in different animal species (1.39 \< *λ*\< 1.77 \[[@CR69]\]---note that this is a relatively wide range because it implies a 40% difference in *D*\*, which can influence significantly the extent of postsynaptic receptor activation \[[@CR70]\]). Multiple factors contribute to *λ*: the geometry of the ECS (e.g. number and shape of neighboring structures), dead-end microdomains \[[@CR71]\], the ECS viscosity due to the presence of proteins and various macromolecules within the extracellular matrix, as well as any interactions between neurotransmitters and receptors or charged molecules in the ECS \[[@CR68]\]. The geometric and viscous components of *λ* are often referred to as *λ*~g~ and *λ*~v~. In a simplified 3D environment where the ECS resembles a series of packed convex cells, one could consider *λ* = *λ*~*g*~ · *λ*~*v*~ (but see \[[@CR72], [@CR73]\] for a more detailed mathematical evaluation of how dead-end pores contribute to brain tortuosity). The numerical range across which *λ*~g~ can vary is described by the equation \[[@CR68], [@CR74]\]: $$\documentclass[12pt]{minimal}
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\begin{document}$$ {\lambda_{\text{g}}} = \sqrt {\frac{{3 - \alpha }}{2}} $$\end{document}$$Therefore, for 0 \< *α* \< 1, one has 1 \< *λ*~g~ \< 1.225. The discrepancy between this upper limit for *λ*~g~ and the experimental value of *λ* = 1.6 is likely due to *λ*~v~, the specific/non-specific binding effects mentioned previously (whose effective contribution to *λ*, however, remains undetermined) and the greater morphological complexity of the brain.

A quantitative estimate of α and *λ* is not necessarily trivial. Whereas various methods have been explored to estimate *D*\* or *λ* \[[@CR75]--[@CR78]\], a simultaneous measure of *α* and *λ*, including both the viscous and the geometrical component, has only been obtained initially with radiotracers \[[@CR79]\] and later on with real-time iontophoresis \[[@CR67]\]. The use of radiotracers has been hampered by the fact that they require long perfusion times and post-mortem processing of the tissue \[[@CR69]\]. The iontophoresis technique involves monitoring the diffusion of small (MW \< 100 Da), cell-impermeable ions (e.g., tetramethylammonium, tetraethylammonium, α-naphthalene sulfonate) from an iontophoresis electrode to an ion-selective one, mounted at a fixed distance from each other (few hundreds of micrometers) \[[@CR67]\]. The signal detected by the ion-selective electrode is displayed as a diffusion curve which is used to extract the values of *α* and *λ* (in addition to *k*′, a measure of neurotransmitter loss \[[@CR67]\]). The main caveat of this approach, as pointed out by \[[@CR75]\], is that it only provides information about diffusion of small molecules towards one point in the tissue without resolving possible spatial patterns of diffusion. This limitation can be partly overcome with integrative optical imaging approaches \[[@CR75], [@CR77]\]. By monitoring the diffusion profile of fluorescently labeled molecules with high molecular weight (e.g. Texas Red dextrans up to tens of kilodaltons \[[@CR75]\] or quantum dots \[[@CR77]\]), one can derive *D*\* for smaller neurotransmitter molecules. The technique relies on a mathematical description of the image of the three-dimensional diffusion of dyes on a two-dimensional plane. To avoid this step, which nevertheless approximates the experimental results reasonably well \[[@CR77]\], and to gain an even better time resolution of diffusion, the time--space profile of small fluorescent molecules (e.g., Alexa Fluo 350) can be examined in a thin focal plane, like that of a two-photon laser scanning microscope \[[@CR76], [@CR78]\]. In all cases, it is assumed that dyes diffuse in the ECS with radial symmetry from a point source. The goodness of this approximation can be verified post-hoc by analyzing the goodness of a Gaussian fit of the diffusion profile of the dye, which generally holds.

An exhaustive comparison of how the estimate of the diffusion parameters vary with different experimental approaches is still missing. Although in principle the two-photon approach offers the best spatial and time resolution, it remains unclear whether this effectively improves the accuracy of the numerical estimates. The major caveat common to all approaches, in our opinion, is that they all provide bulk measures of diffusion over distances (tens or hundreds of micrometers) and times (milliseconds) that largely exceed the spatiotemporal scales of synapses (nanometers, microseconds). An estimate of *D*\*~glutamate~ from physiological experiments has been performed by Nielsen et al. \[[@CR80]\] through an evaluation of the effect of dextran on the kinetics and amplitude of spillover-mediated currents at cerebellar mossy fiber-granule cell synapses $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\left( {D^{*}_{{{\text{glutamate}}}} = {0.33 \pm 0.13\,\mu {\text{m}}^{{\text{2}}} } \mathord{\left/ {\vphantom {{0.33 \pm 0.13\,\mu {\text{m}}^{{\text{2}}} } {{\text{ms}};\,{\text{mean}} \pm {\text{S}}{\text{.E}}{\text{.M}}{\text{.}}}}} \right. \kern-\nulldelimiterspace} {{\text{ms}};\,{\text{mean}} \pm {\text{S}}{\text{.E}}{\text{.M}}{\text{.}}}} \right)} $$\end{document}$, but it is currently unknown whether this estimate can be considered reasonably accurate for other types of synapses.

One major point of uncertainty is whether any change in neurotransmitter diffusion occurs between the synaptic cleft and neighboring extrasynaptic regions. Given that the majority of the tortuosity factor is contributed by geometrical factors, and there is no geometric obstacle to diffusion in the synaptic cleft, it could be feasible that *D*\*~cleft~ \<\< *D*\*~extrasynaptic\ areas~ \[[@CR81]\].

Why is it relevant to have such a meticulous estimate of *D*\* and *λ* in the brain? Slowly diffusing neurotransmitters persist in the ECS for a relatively long time, and have higher chances of binding to receptors. Therefore, by altering the neurotransmitter concentration profile, varying *D*\* can also alter the open probability of receptors, as long as these are far from saturation. Indeed, this prediction has been tested in a number of simulation environments for a range of *D*\* = 0.1--0.75 μm^2^/ms \[[@CR80], [@CR82], [@CR83]\] (here the upper value equals the diffusion coefficient of glutamine in free medium at 25°C \[[@CR84]\]) and also experimentally \[[@CR85]\]. For example, at hippocampal mossy fiber synapses on CA3 pyramidal cells, lowering *D*\*~glutamate~ by 50% enhances significantly activation of AMPAR, NMDAR, and kainate receptors \[[@CR85]\]. Whether even smaller changes in *D*\* can still lead to physiologically relevant effects on receptor activation and inter-neuronal signaling remains to be evaluated: varying *D*\* alters the neurotransmitter concentration profile, but whether this leads to small or big changes in postsynaptic responses depends on the properties of the activated receptors. By using the kinetic models of four receptor types described in Fig. [1](#Fig1){ref-type="fig"}, we have analyzed how significant changes in receptor activation could occur with neurotransmitter transients of different amplitude and duration (Fig. [2](#Fig2){ref-type="fig"}). A wide range of uncertainties in the estimate of the neurotransmitter concentration profile can alter significantly the peak open probability of postsynaptic receptors. For example, the extent of AMPAR activation is particularly susceptible to changes in the profile of the neurotransmitter transient. One could then speculate that this may alter profoundly the temporal integration of synaptic inputs, given the high temporal precision with which certain synapses can operate \[[@CR86]\]. Fig. 1The kinetic models used to estimate the time course of transmitter detected by NMDARs \[[@CR105]\], AMPARs \[[@CR88]\], glycine \[[@CR107]\] receptors or for a generic agonist-receptor model \[[@CR118]\]. All rates are taken from the original publications and are expressed in ms^−1^ or mM^−1^ ms^−1^, as appropriate. The rates for the model of del Castillo and Katz \[[@CR118]\] are adapted to produce a current with a *τ*~decay~ = 6 ms. Agonist molecules are indicated by *A*, resting states of the receptor by *R*, and open states by an *asterisk*. *F* indicates the flipped state of a receptor, whereas the subscript *d* identifies desensitized states. *B* represents blocker molecules (e.g., low-affinity antagonists). Reactions in *black* have been used to simulate the synaptic responses in Fig. [2](#Fig2){ref-type="fig"}; reactions in *gray* represent binding of low-affinity antagonist blockers to their corresponding receptor molecules (D-AA, kynurenic acid and SR-95531 for NMDARs, AMPARs and glycine receptors, respectively). All reactions, in black and in gray, have been used for the analysis presented in Fig. [4](#Fig4){ref-type="fig"}Fig. 2Effect of altering the profile of the neurotransmitter transient on the occupancy of different receptors. We used a simplified version of the kinetic models described in Fig. [1](#Fig1){ref-type="fig"}, where the reactions between receptors and antagonists have been removed (i.e., only the reaction steps in black). *top row* Dependency of peak open probability (*Po*) on the duration of monoexponential agonist pulses of different concentration (0.1, 1, and 5 mM). *bottom row* Dependency of receptor occupancy (*Po*) on the amplitude of a 1 ms long agonist transient. The *insets* display examples of simulated receptor responses to different agonist pulses. All simulations were run in ChanneLab (Synaptosolf, Inc.), using a Runge--Kutta 4 integration

The effects of changes in *D*\* could be particularly pronounced for extrasynaptic receptors scattered around the postsynaptic density and in dendritic shafts \[[@CR70]\]. For example, at glutamatergic synapses the occupancy of high-affinity slow-desensitizing NMDARs may be enhanced by increasing the overall tortuosity of the synaptic and non-synaptic milieu \[[@CR83]\]. The physiological relevance of a differential activation of extrasynaptic receptors remains a matter of current investigation.

Needless to say, activation of these distant receptors is extremely susceptible to the presence, distribution, and relative abundance of transporters which can quickly buffer neurotransmitter molecules in hundreds of microseconds \[[@CR39], [@CR87], [@CR88]\] and slowly remove them from the ECS, at rates that depend on the membrane potential, temperature, and concentration of co-transported ions (\~4--27 s^−1^ for *V*~R~ = −140--0 mV, at RT \[[@CR89]\]). A quantitative analysis of glutamate transporter density has been performed by Lehre and Danbolt \[[@CR90]\], and appears to vary among different brain regions, depending on the developmental stage of the preparation. For example, in adult rats, the glutamate transporter GLT-1 is more abundantly expressed in hippocampal CA1 *stratum radiatum* (8,500 μm^−2^) than in cerebellar *stratum moleculare* (740 μm^−2^), but it is barely detectable in newborn rats \[[@CR91]\]. In agreement with this developmental trend, the time course of glutamate clearance derived from astrocytic recordings in rat hippocampal *stratum radiatum* also becomes faster between P12-14 and \>P60 \[[@CR92]\]. The contribution of transporters to glutamate clearance is enhanced at physiological temperature (perhaps not surprisingly: the temperature dependence of neurotransmitter uptake (*Q*~10~ = 3) is steeper than that of diffusion (*Q*~*10*~ = 1.3)) \[[@CR43]\] and may be exacerbated during repetitive presynaptic stimulations \[[@CR93]\].

The activity of glial glutamate transporters has also been analyzed in the context of activation of particular receptor subtypes that have inhomogeneous subcellular distributions, like metabotropic glutamate receptors \[[@CR94]\] or NR2B-containing NMDARs \[[@CR95]\]. However, an exhaustive characterization of the role of neuronal glutamate transporters is lacking. Perisynaptic EAAT4 has been shown to control activation of metabotropic receptors in Purkinje cells \[[@CR96]\], although not in regions lacking the protein zebrin II \[[@CR97]\]. A definitive understanding of the role of EAAT3 is currently missing \[[@CR98]\], partly because there is no sensitive antibody or specific pharmacological compound that can specifically target this molecule. Recent experimental and theoretical estimates suggest that EAAT3 could have a potentially pivotal role in regulating the profile of the glutamate transient \[[@CR78], [@CR98]\].

Mathematical Simulations of Synaptic Currents {#Sec6}
=============================================

The first attempts to calculate the time course of neurotransmitter release in the peripheral system were performed at a time when anatomical details about the shape and size of the synaptic cleft were still unavailable \[[@CR99], [@CR100]\]. These estimates, obtained by simply applying the formula for unhindered diffusion of a substance from a point source into free medium, were not necessarily aimed at providing a faithful representation of the neurotransmitter transient, yet they informed us on the ballpark time window over which diffusion of neurotransmitters could occur and triggered a long-lasting debate on the role of this phenomenon in shaping the profile of synaptic currents. A step forward was made in the late 1950s by Eccles and Jaeger \[[@CR61]\], who performed a more explicit mathematical analysis of ACh diffusion in disk- or strip-like synaptic clefts where diffusion in the *z*-dimension was prevented by the presence of presynaptic terminals and subsynaptic membranes. The estimated time course of neurotransmitter concentration had an approximately exponential behavior with a half decay time of \~2 ms that roughly matched the time course of intracellularly recorded EPPs \[[@CR101]\].

This general approach, however, could be implemented by including a description of receptor kinetics and a more realistic geometry of the synaptic environment and the surrounding neuropil. Numerically, this can be achieved by using a series of differential equations that describe the transitions between different receptor complexes and the distribution of neurotransmitter molecules by a continuous density function of space and time. This method is generally preferred when dealing with simple reaction schemes and geometries and when numerical accuracy is required because the error can be progressively reduced by increasing the number of points at which the estimated density function is derived \[[@CR102]\].

More complex frameworks that include detailed 3D reconstructions of synaptic structures can also take advantage of Monte Carlo simulations, which deliberately aim to illustrate the stochastic nature of diffusion of finite numbers of molecules. Here, diffusion is treated probabilistically and the position of neurotransmitter molecules is followed in 3D coordinates and time \[[@CR102]--[@CR104]\]. The generated waveforms, in this case, appear noisy due to the nature of the simulated stochastic processes. The error is proportional to (*nN*)^−0.5^, where *n* = number of simulated runs and *N* = number of neurotransmitter molecules.

Although these approaches can be used to explore the role of morphological and kinetic variables on synaptic currents, their predictive values is inevitably hampered by uncertainties associated with most of the parameters that are being used. Within a certain cell population, for example, there can be such a wide range of synapses differing in their structure, size, number and distribution of receptors, release properties, and glial coverage \[[@CR5]--[@CR10]\], that the derived "average" neurotransmitter profile may occur only at a small fraction of all synaptic contacts.

It is also worth noting that, to some extent, the neurotransmitter profile concentration varies with the distance from an active release site, as illustrated in Fig. [3](#Fig3){ref-type="fig"}. In most instances, it does not perfectly follow the profile of a simple monoexponential function (particularly long after release has occurred). Therefore, the notional measurements of the neurotransmitter concentration profile in the cleft often represent an *averaged* spatiotemporal concentration profile across the whole postsynaptic region, where the receptors contributing to synaptic responses reside. It should not be interpreted as a faithful representation of the neurotransmitter concentration profile experienced by all the receptors distributed anywhere across the entire postsynaptic area. Fig. 3Monte Carlo simulation of neurotransmitter diffusion in a disk. The neurotransmitter (*red dots*) diffuses in a disk (height *h* = 20 nm, radius *r* = 250 nm, white wireframes) representing the apposition zone between pre and postsynaptic terminals (i.e., the cleft). At *t* = 0, 2000 neurotransmitter molecules are released from a point source at the center of the disk, and diffuse with an apparent diffusion coefficient of 3.3 cm^2^/s \[[@CR80]\]. **a** Snapshots of neurotransmitter diffusion 1--2--4--8 μs after release. **b** Side view of neurotransmitter diffusion in the cleft, at the times indicated in **a**. **c** Top view of the apposition zone. This is divided in three concentric disks and annuli, with outer radii *r* = 110--180--250 nm, respectively. The *red arrows* indicate the mean distance between each disk or annulus and the release site. **d** Examples of the glutamate waveforms monitored in each one of the three volumes described in **c**. Each trace represents the average of 100 Monte Carlo runs, iterated for 10^4^ times with *Δt* = 1 μs. The geometry was created in silico with an open source program (Blender), imported in a Monte Carlo simulation environment (MCell) and rendered with the visualization software DReAMM \[[@CR143], [@CR144]\]

The Competitive Low-affinity Antagonist Method {#Sec7}
==============================================

The use of competitive antagonists with a fast unbinding rate for estimating the time course of neurotransmitter in the cleft was introduced by Clements et al. \[[@CR105]\], who estimated the glutamate transient at excitatory synapses in cultured hippocampal neurons using a low-affinity competitive NMDAR antagonist. When postsynaptic receptors are in equilibrium with the antagonist at a *K*~d~ concentration, on average half of them are occupied by the drug (assuming there is only one antagonist binding site on each receptor). If the average lifetime of the antagonist--receptor bound complex is much longer than the length of the agonist pulse, the response in the presence of the antagonist is half of that observed in control. If, however, the unbinding rate of the antagonist is comparable with the length of the agonist pulse, at least some antagonist molecules unbind and leave the receptor available for binding the agonist and eventually open. In this case, two predictions can be made: first, the current response is less inhibited than calculated at equilibrium. Second, the rise time of the current response is slowed down in the presence of antagonist, because at least some agonist molecules bind (and activate) the receptor only after the antagonist molecules are unbound. Both predictions are confirmed by direct experimental observations in excised patches using antagonists for NMDARs \[[@CR105]\], AMPARs \[[@CR88]\], GABA~A~Rs \[[@CR106]\], and glycine receptors \[[@CR107]\]. More importantly, the amount of inhibition depends on the actual profile of transmitter in the cleft: the longer the receptors are exposed to the agonist, the more antagonist molecules unbind and are replaced by agonist. In the case of glutamate and glycine receptors, a full dose-inhibition curve of synaptic currents is available \[[@CR98], [@CR105], [@CR107]\]. The data are fitted using only the peak agonist concentration and its clearance time as free parameters and the best fits are obtained with agonist pulses of at least 1 mM and shorter than 1 ms.

This method is rather ingenious and can be implemented with technically straightforward experiments. However, there are a number of uncertainties for its application: first, this approach relies on the exact knowledge of the kinetic properties of postsynaptic receptors and the values for the binding and unbinding rates of the antagonist. The first can be obtained either from the kinetic analysis of single channel recordings \[[@CR108], [@CR109]\] or from the analysis of macroscopic currents exposed to a fast agonist transient \[[@CR105], [@CR110], [@CR111]\]. While the single-channel approach allows estimate of several rate constants even in models with many different kinetic states \[[@CR109], [@CR112]\], it does not provide information on the kinetics of desensitization, for example. In addition, single-channel experiments can only be performed on channels whose conductance is big enough to allow good time resolution, like glycine receptors \[[@CR109], [@CR113]\] or NMDARs \[[@CR114]\], having limited utility for channels with lower conductance (GABA~A~R and AMPARs), for which ultra-fast concentration jumps are preferred. However, due to the high time correlation between adjacent points \[[@CR115]\] only few parameters can be estimated with this method, although a number of different experimental protocols can provide enough information to determine the rates in a simplified model that can give a good description of the experimental results. It is worth noting, however, that the estimates of these kinetic rates are generally obtained from extrasynaptic receptors, since access to synaptic ones is hard to achieve (but see \[[@CR116]\]). This raises the possibility of differences between the two populations of receptors (the ones activated during synaptic events and those studied for kinetics analysis) that could be due to different subunit composition, the modulatory effects of anchoring proteins, intracellular kinases and phosphatases that are lost following patch excision or the effect of channel density \[[@CR117]\], all factors that are difficult to assess experimentally.

Furthermore, in order to limit the number of fitted parameters, the transmitter pulse is generally modeled as an exponential function, while the actual neurotransmitter time profile obtained from solving diffusion equations may deviate from this simplified profile (see also Fig. [3](#Fig3){ref-type="fig"}). The exponential approximation used by most authors, however, allows for a straightforward comparison of the various available estimates. The most notable limitation of the competitive low-affinity antagonist approach is that for a given concentration of antagonist, the same amount of inhibition of the control response can be observed with either a short pulse of high agonist concentration or a long pulse of low agonist concentration \[[@CR98]\]. In the first case, few antagonist molecules unbind during the (short) pulse, but they are quickly replaced by the agonist present at high concentration. In the opposite case, there are a lot more antagonist molecules that unbind during the (long) pulse, but they are effectively replaced by agonist molecules over the course of the prolonged low-concentration transient. This limitation (first indicated by Diamond \[[@CR98]\]) can be observed in the top row of Fig. [4](#Fig4){ref-type="fig"}, where the values of peak agonist concentration and decay time that give a 50% inhibition at *K*~d~ concentration of a fast competitive antagonist are calculated for published kinetic models of NMDARs \[[@CR105]\], AMPARs \[[@CR88]\], glycine receptors \[[@CR107]\], and for a standard del Castillo--Katz model \[[@CR118]\] (see Fig. [1](#Fig1){ref-type="fig"} for details on the kinetic rates of each model). It is clear that very different concentration time courses give rise to the same level of observed inhibition for all four different receptors. This feature is entirely independent of the exact details of the model (number of binding sites, open states, intermediate shut states, and desensitization rates all differ in the models included in the figure), and accordingly is observed with the simplest model where agonist and antagonist compete for a single binding site (last column of Fig. [4](#Fig4){ref-type="fig"}). Fig. 4The peak concentration and time course of neurotransmitter in the cleft is not unambiguously determined by low-affinity antagonists. *top row* The continuous line in the plots shows the combined values of neurotransmitter peak concentration and decay time that can give rise to 50% inhibition by low-affinity antagonists. For each receptor kinetic model, we calculated a dose--inhibition curve with seven concentrations of antagonists, for 1 mM · 1 ms agonist pulse. The dose--inhibition curve was then fitted using the peak agonist concentration and decay time as the only free parameters. The best fit was invariably obtained for values very close to 1 mM 1 ms. *bottom row* Calculated 95% confidence limit for each fit. The fits span a 1- or 2-orders-of-magnitude range around the best parameters, with a high correlation coefficient (\>0.99). This implies that despite convergence of the fitting routine, the two fitted parameters (i.e., neurotransmitter peak concentration and decay time) are substantially undetermined

When the results of experiments performed with many antagonist concentrations are put together the fit of the resulting dose--inhibition curve with the peak agonist concentration and decay time as free parameters does not resolve this ambiguity. To prove this, the responses to an agonist pulse of 1 mM with *τ*~decay~ = 1 ms are calculated from the *Q* matrices (where *Q* is defined as the matrix containing the transition rates to and from all states present in the model \[[@CR119]\]) corresponding to the four models of Fig. [1](#Fig1){ref-type="fig"} by solving with an adaptive Runge--Kutta integration (RK5) the differential equations that describe the current time course \[[@CR120]\]: $$\documentclass[12pt]{minimal}
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\begin{document}$$ \overrightarrow P (t) $$\end{document}$ is the row vector of occupancies of each of the states of the model and *Q(t)* is the matrix with the transition rates. The current amplitude is calculated as the sum of the occupancies of the open states. A dose--inhibition curve is determined for seven antagonist concentrations (attaching a 7% error to each calculated point, in line with previously published data \[[@CR98], [@CR105], [@CR107]\]). The time course of agonist in the cleft (*A*(*t*)) is described by the function: $$\documentclass[12pt]{minimal}
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\begin{document}$$ A(t) = \left\{ {\begin{array}{*{20}{c}} {0 \cdots \cdots \cdots \cdots \cdots \cdots {\text{if}} \cdots t<0} \\ {{A_{\text{peak}}} \times {{\rm e}^{ - \frac{t}{\tau }}} \cdots {\text{if}} \cdots t \geqslant 0} \end{array} } \right. $$\end{document}$$and the values of *A*~peak~ and *τ*~decay~ that give the best fit of the dose--inhibition curve are determined with a fitting routine written in Interactive Data Language (IDL, from ITT Visual Information solutions, Boulder, Colorado) that uses a Levenberg--Marquardt algorithm to minimize the sum of squared deviation (SSD) from the data points.

The fitting routine invariably converges to the correct values (±1% typically). However, the error on the calculated estimates is always bigger than one order of magnitude (in a logarithmic scale) for both parameters. This is because the two variables are heavily correlated (*r* varying between 0.996 and 0.999 among the four models tested). We have therefore determined the region of the two-dimensional parameter space in which the values of the SSD deviates from the minimum by less than *t*^2^, where *t* = 2.57 is the value of the Student's *t* statistic with 5 degrees of freedom (the seven simulated data points minus the two estimated parameters) that corresponds to the arbitrarily chosen 95% confidence limit. In other words, all the parameters included in this region provide an equally good fit of the dose--inhibition curve. As seen in the plots in the bottom row of Fig. [4](#Fig4){ref-type="fig"}, for all four models, the possible parameters describing the concentration profile extend over most of the parameter space in which the search is performed and are therefore completely undetermined.

The method of the competitive low-affinity antagonist alone cannot produce unambiguous results, even when the number of fitted parameters is limited to two. In order to overcome this problem, Overstreet et al. \[[@CR106]\] estimated that GABA reaches a cleft concentration of 3--5 mM, that decays with *τ*~decay~ = 0.3--0.6 ms, using a single antagonist concentration and performing a fit of the whole time course of GABAergic IPSCs. With this method, information contained in the amplitude variation and in the change in rise time induced by the antagonist is simultaneously included. As a result, the confidence limits in the estimates of the two parameters are much narrower and no correlation is apparent (see Fig. 16.6B in \[[@CR106]\]). One possible limitation of this approach is that it relies on a perfect match between the kinetic properties of synaptic receptors and the extrasynaptic ones that are used for determining the kinetic rates that we mentioned \[[@CR121]\]. Furthermore, especially in brain slices (as opposed to cultured neurons), the observed rise times of PSCs are affected by the intrinsic filtering of the recording apparatus (parallel circuit of series resistance and whole cell capacitance) as well as by the cable filtering, which is more severe for release sites that are farther away from the soma. Therefore, fitting the time course of observed PSCs to a kinetic scheme has some intrinsic limitations, especially for fast currents like AMPAR or glycine mediated ones. In \[[@CR88]\], the authors established the glutamate concentration in the cleft by combining information from the dose--inhibition curve and the changes in rise time observed with the antagonist and/or with a blocker of glutamate transport. Through this approach, it was shown that the glutamate transient is best described by a double exponential waveform with peak concentrations of 2.7 and 0.4 mM and with *τ*~decay~ = 0.1 ms and *τ*~decay~ = 2.1 ms, respectively. Blocking transporters has the advantage that it can change the clearance time with negligible effects on the neurotransmitter peak concentration and therefore can be assumed to alter independently one of the two correlated parameters. Accordingly, the comparison of inhibition before and after block of transporters has been instrumental in determining the time course for glutamate at AMPARs \[[@CR88]\] and of glycine at synapses onto motoneurons in the spinal cord \[[@CR107]\].

A different but conceptually similar method has been used for determining the time course of synaptically released GABA in cultured hippocampal neurons. Instead of partially occupying the agonist binding sites with an antagonist, the authors used modulators like chlorpromazine or zinc \[[@CR122], [@CR123]\] or pH manipulations \[[@CR110]\] that affect (mostly) the agonist binding rates. These manipulations, as noticed by the authors, affect macroscopic currents evoked by ultra-fast application of transmitter differently from synaptic currents. This is attributed to differences between the time course (and in particular *τ*~decay~) of the ultra-fast application and that of synaptically released GABA. This discrepancy, together with the determination of the kinetic rates before and after application of the modulatory agent, allows determining the time course of GABA release. The estimate still relies on an exact description of the kinetics of postsynaptic receptors. However, its goodness is strongly supported by the fact that very similar values for the peak concentration and *τ*~decay~ (2--3 mM and 0.1 ms, respectively) are estimated with the three independent approaches (i.e., chlorpromazine, zinc, and variations in pH).

Sniffers and Imaging Approaches {#Sec8}
===============================

Various attempts have been made to develop glutamate sensors as reporters of neurotransmitter release. Excised patches of cell membranes enriched with high-affinity receptors, for example, have been used to probe the identity of the neurotransmitter released from retinal bipolar cells \[[@CR124], [@CR125]\]. The power of this clever design, which in principle can offer a highly sensitive and temporally precise read-out of the glutamate transient (depending on the properties of the receptors in the "sniffer-patch"), is once again hampered by the relative inaccessibility of the cleft region at central synapses.

Although the development of such an ideal experimental tool is still in progress, a number of promising attempts have been made taking advantage of biochemical engineering and high-resolution optical detection methods. The trick here is to have fast and sensitive glutamate reporters combined with high temporal and spatial resolution detection of the glutamate transient, but as it might be expected, the real scenario involves some trade-offs between all these parameters.

Namiki et al. \[[@CR126]\] developed an optical glutamate probe (glutamate (E) optical sensor, EOS) based on a mutated AMPAR GluR2 S1S2 ligand-binding domain fused with the Oregon green dye. The conformational change of the ligand-binding domain induced by glutamate leads to 40% increase in the maximal fluorescence intensity of Oregon green, at the peak of its emission wavelength (520 nm). The kinetics of the reaction is dictated by the rate of glutamate binding to the S1S2 domain (10^7^ M^−1^ s^−1^, if this remains comparable to that of native S1S2 domains) and the measured off-rate (0.67 s^−1^) \[[@CR126]\]. The slow dissociation kinetics, together with a relatively low EC~50~ (148 nM), limit the application of EOS to the late and prolonged phases of neurotransmitter release. In addition, anchoring of EOS to the cell membrane through a generic biotin--streptavidin reaction currently precludes any cell-specific expression of this reporter.

Some of these limitations can be potentially overcome by using optical probes that are genetically encoded, and that at least in principle can be fused with proteins selectively expressed in synaptic or non-synaptic regions. Recent examples of these genetically encoded optical probes are the glutamate-sensing fluorescent reporter (GluSnFR) \[[@CR127]\], the more sensitive variant SuperGluSnFR \[[@CR128]\], or the fluorescence indicator protein for glutamate (FLIPE) \[[@CR129]\]. The general design of these reporters involves fusion of a cyan and yellow fluorescent protein (CFP and YFP, respectively) to the periplasmic glutamate-binding protein from *E. coli* (GltI), and a truncated PDGF receptor that ensures membrane anchoring of the construct \[[@CR128]\]. The CFP and YFP are chosen because they currently represent the best pair of fluorescent proteins enabling fluorescence resonance energy transfer (FRET) \[[@CR127]\]. The conformational change in the S1S2 domain induced by glutamate binding brings the two fluorophores closer to each other (\<80 Å) leading to the non-radiative energy transfer from CFP to YFP detected in FRET experiments (the emission spectrum of CFP significantly overlaps with the excitation spectrum of YFP). A series of mutations of this construct has significantly improved its affinity for glutamate and the extent of CFP/YFP emission ratio upon glutamate binding (in Ringer solution, *K*~d~ = 2.5 μM and 44% change in CFP/YFP emission \[[@CR128]\]). The estimated kinetic properties of SuperGluSnFR, however, seem best suited for detecting small and slow glutamate transients like those occurring during the tail of a synaptic event or during spillover-activation of nearby receptors, as opposed to those that are attained in the synaptic cleft region. For example, in cultured hippocampal neurons, the glutamate transient reported by SuperGluSnFR has a 20--80% rise time = 6.6 ms, \[Glu\]~peak~ = 720 nM, *τ*~decay~ = 40 ms, but the subcellular resolution of the signal is limited by the camera resolution.

A wide range of imaging techniques could also provide useful quantitative insights into the diffusion properties of various molecules inside and outside the synaptic cleft \[[@CR130]\]. For example, fluorescence recovery after photobleaching (FRAP), fluorescence loss in photobleaching (FLIP), and fluorescence localization after photoactivation (FLAP) could, in principle, be used to estimate the characteristics of neurotransmitter diffusion among distinct subcellular compartments.

With FRAP, the experimental preparation is first equilibrated with a fluorophore, which is then bleached in a small region with a high-intensity light source (e.g., a laser). The rate and extent of fluorescence recovery can be followed in time, providing information on the fluorophore diffusion between the bleached region and neighboring ones. This method has been used to analyze inhomogeneities in the diffusion coefficient of small and large particles within the cytoplasm \[[@CR131]\]. A modified but related approach consists of constantly bleaching the fluorophore at a particular site and monitoring the FLIP at a nearby location to examine the exchange in fluorescence between the bleached and neighboring sites. If the fluorophore has similar biophysical properties to those of the neurotransmitter of interest, one could possibly determine how far and how quickly it travels away from the bleached area \[[@CR132]\]. The general principles of these two techniques are also shared by FLAP, where one follows the localization of a photoactivated molecule, like PA-GFP \[[@CR133]\] or Dronpa \[[@CR134]\], or of a fluorescent molecule that changes its spectrum of emission upon exposure to UV light (e.g., Kaede \[[@CR135]\]). The advantage of these techniques is that they can be used in confocal or two-photon microscopy set-ups, but are limited, however, by the temporal and spatial resolution of these systems.

That is why the development of other techniques has become so crucial. Particularly noteworthy are fluorescence lifetime imaging (FLIM) and fluorescence correlation spectroscopy (FCS) \[[@CR136]\], which have sub-microsecond time limits, or photoactivated localization microscopy (PALM) and single-particle tracking PALM (sptPALM) \[[@CR137]\], which significantly enhance the spatial resolution of the signal emitted by labeled molecules \[[@CR138], [@CR139]\]. With FLIM, one measures the exponential decay in the emission intensity of a fluorophore (i.e., its lifetime). This measure is independent of the fluorophore concentration, but changes if the environment surrounding the fluorophore (e.g., polarity, ion concentration, and viscosity) alters its electronic state. Fluorescence lifetimes can be measured in the time and frequency domains, and have been used in biological systems to measure ionic concentrations (Ca^2+^, Cl^−^, O~2~) or the subcellular localization of various macromolecules \[[@CR140]\]. This technique can also be combined with FCS \[[@CR141]\] to determine the diffusion coefficient of fluorescent molecules within a known volume \[[@CR140]\]. An interesting variation of FCS, scanning FCS (sFCS), does not require a priori knowledge of the measurement volume, and therefore is probably better suited for diffusion estimates in living systems \[[@CR142]\].

A recently developed approach, sptPALM, has enabled tracking of single fluorescent protein chimeras with nanometer spatial resolution. This allows one to obtain maps of single-molecule diffusion that can be useful to study cell dynamics, as well as the properties of subcellular microenvironments. It would be of interest to test whether this kind of approach could be used to study the diffusion profile of smaller molecules, like neurotransmitters, particularly in living tissues. These and other techniques are constantly being refined and their application to synaptic physiology is expected to enable the investigation of aspects of synaptic transmission and neurotransmitter diffusion that are currently precluded by indirect pharmacological and modeling approaches.

Conclusions {#Sec9}
===========

The problem of the determination of the time course of transmitter in the cleft has spanned more than 60 years of neuroscience research and a number of direct and indirect approaches have been used to determine this elusive variable. Despite all the efforts, we are still far from a definite consensus, even for the most studied synapses in the central nervous system. Old techniques and innovative approaches have been devised that are continuously challenged by the advent of improved technologies that can resolve events on a faster time scale and with better spatial resolution. In this review, we highlighted the advantages and pitfalls of each method that has been used in the past and analyzed the potential of new optical techniques that in the future could provide quantitative descriptions of the fundamental mechanisms underlying the dynamics of inter-neuronal signaling. It is likely that refinement of these novel approaches will ultimately answer many open questions that have haunted neuroscientists since the demonstration of quantal release of neurotransmitter as the main form of communication between neuronal cells.
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